131 / 1631
Designing a clinical trial of RT + checkpoint
blockade for relapsed and refractory FL
Hypothesis
Low-dose RT plus anti-PD-L1 Ab (atezolizumab) is safe and
able to improve systemic responses compared to atezolizumab
alone